{"id":"W2947468545","doi":"10.1186/s12885-019-5266-4","title":"Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Durvalumab; Tremelimumab; Immunotherapy; Oncology; Clinical endpoint; Head and neck squamous-cell carcinoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Surgical oncology; Common Terminology Criteria for Adverse Events; Adverse effect; Phases of clinical research; Radiation therapy; Radiology; Head and neck cancer; Toxicity; Cancer; Clinical trial; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002041631,0.001963483,0.002851641,0.0004357292,0.0005007175,0.001049885,0.001216989,0.001386391,0.003683871],"category_scores_gemma":[0.000772316,0.0007083437,0.001252792,0.0003729499,0.001176836,0.0008226791,0.0003920065,0.003293811,0.0009084179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00140005,"about_ca_system_score_gemma":0.002763184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001801749,"about_ca_topic_score_gemma":0.004552328,"domain_scores_codex":[0.9995364,0.0001942079,0.00002405163,0.00008817209,0.0000561693,0.0001010116],"domain_scores_gemma":[0.9991321,0.0001118271,0.0001350359,0.00006176808,0.00004786751,0.0005113331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8081546,0.09215994,0.004158757,0.0007254239,0.001602658,0.0002350398,0.0002396365,0.002491302,0.03190437,0.0003157171,0.00337763,0.05463491],"study_design_scores_gemma":[0.638544,0.3514994,0.004722191,0.00002145072,0.0003686124,0.0001680029,0.0000335606,0.001166927,0.00222503,0.0001501724,0.001080535,0.00002024134],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939469,0.001017501,0.000351323,0.0003770828,0.0001610921,0.002373224,0.0005061745,0.00006927863,0.001197316],"genre_scores_gemma":[0.9892224,0.001212368,0.001594172,0.0008384527,0.0002339847,0.002771951,0.001503169,0.00002101457,0.002602537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003683871,"threshold_uncertainty_score":0.01232374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0591299704651508,"score_gpt":0.3773384111575256,"score_spread":0.3182084406923749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}